Affected by 63I-2-236 on 12/31/2023 Effective 5/4/2022 36-29-301. Definitions. As used in this part: (1) “Department” means the Department of Health and Human Services created in Section 26B-1-201. (2) “Executive director” means the executive director of the department. (3) “Psychotherapy drug” means a controlled substance that: (a) is not currently available for legal use; and […]
Affected by 63I-2-236 on 12/31/2023 Effective 5/4/2022 36-29-302. Creation and membership. (1) There is created the Mental Illness Psychotherapy Drug Task Force. (2) The task force shall be chaired by: (a) the executive director or the executive director’s designee; and (b) the chief executive officer of the Huntsman Mental Health Institute at the University of […]
Affected by 63I-2-236 on 12/31/2023 Effective 5/4/2022 36-29-303. Duties. (1) (a) The task force shall provide evidence-based recommendations on any psychotherapy drug that the task force determines may enhance psychotherapy when treating a mental illness. (b) For a psychotherapy drug described in Subsection (1)(a), the task force shall provide recommendations on: (i) types or symptoms […]
